← Back to Screener
Mustang Bio, Inc. (MBIO)
Price$0.74
Favorite Metrics
Price vs S&P 500 (26W)-61.50%
Price vs S&P 500 (4W)-17.09%
Market Capitalization$5.61M
All Metrics
Book Value / Share (Quarterly)$1.31
P/TBV (Annual)0.32x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-0.72
Price vs S&P 500 (YTD)-28.52%
EPS (TTM)$-0.40
10-Day Avg Trading Volume0.04M
EPS Excl Extra (TTM)$-0.40
EPS (Annual)$-0.39
ROI (Annual)-20.16%
Cash / Share (Quarterly)$2.37
ROA (Last FY)-10.92%
EBITD / Share (TTM)$-0.49
ROE (5Y Avg)-8452.10%
Cash Flow / Share (Annual)$-0.72
P/B Ratio0.59x
P/B Ratio (Quarterly)0.75x
Net Income / Employee (Annual)$-0
Net Interest Coverage (TTM)-14.83x
ROA (TTM)-11.84%
EPS Incl Extra (Annual)$-0.39
Current Ratio (Annual)2.22x
Quick Ratio (Quarterly)2.21x
3-Month Avg Trading Volume0.14M
52-Week Price Return-44.38%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$0.48
52-Week High$7.00
EPS Excl Extra (Annual)$-0.39
Tangible BV CAGR (5Y)-5.01%
26-Week Price Return-54.61%
Quick Ratio (Annual)2.21x
13-Week Price Return-29.54%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)2.22x
Enterprise Value$-11.66
Book Value / Share Growth (5Y)-38.42%
Revenue / Employee (Annual)$0
Cash / Share (Annual)$2.37
3-Month Return Std Dev65.12%
Net Income / Employee (TTM)$-0
ROE (Last FY)-20.16%
Net Interest Coverage (Annual)-12.90x
EPS Basic Excl Extra (Annual)$-0.39
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-0.40
ROI (TTM)-29.78%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$5.82
Price vs S&P 500 (52W)-79.01%
Year-to-Date Return-24.59%
5-Day Price Return-1.36%
EPS Normalized (Annual)$-0.39
ROA (5Y Avg)-121.58%
Month-to-Date Return1.62%
Cash Flow / Share (TTM)$-7.66
EBITD / Share (Annual)$-0.49
LT Debt / Equity (Annual)0.00x
ROI (5Y Avg)-8439.65%
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$-0.40
P/TBV (Quarterly)3.75x
P/B Ratio (Annual)0.75x
Book Value / Share (Annual)$1.31
Price vs S&P 500 (13W)-31.92%
Beta2.14x
Revenue / Share (TTM)$0.00
ROE (TTM)-29.78%
52-Week Low$0.53
Analyst Recommendations
Sep 2024
Oct 2024
Nov 2024
Dec 2024
4.14
4.14
4.14
4.14
Industry Peers — Pharmaceuticals(309)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
MBIOMustang Bio, Inc. | — | — | — | — | $0.74 |
LLYEli Lilly & Co. | 13.45x | 44.70% | 83.04% | 27.59% | $919.90 |
JNJJohnson & Johnson | 5.82x | 7.87% | 67.95% | 14.90% | $230.69 |
ABBVABBVIE INC. | 5.97x | 8.57% | 71.62% | -2.88% | $203.71 |
MRKMerck & Co., Inc. | 4.51x | 1.31% | 78.55% | 21.23% | $117.10 |
AZNAstraZeneca PLC | 5.39x | 8.63% | 81.31% | 21.88% | $200.69 |
NVSNovartis AG | 4.87x | 8.91% | 75.82% | 15.26% | $150.99 |
NVONovo-Nordisk A/S | 3.74x | 6.43% | 80.98% | 20.66% | $40.46 |
ABTAbbott Laboratories | 3.71x | 6.59% | 56.50% | 8.20% | $96.00 |
PFEPfizer Inc. | 2.50x | -1.64% | 75.81% | -3.51% | $27.52 |
BMYBristol-Myers Squibb Co. | 2.52x | -0.22% | 72.63% | — | $59.13 |
About
Mustang Bio is a clinical-stage biopharmaceutical company developing cell and gene therapies to treat hematologic cancers, solid tumors, and rare genetic diseases. The company's pipeline focuses on gene therapies for genetic disorders and CAR T cell therapies targeting hematologic malignancies and solid tumors.